These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10793937)

  • 1. [Prevention of respiratory syncytial virus infection in a peripheral hospital: economic problems and ethical questions].
    Faverge B; Bonein M; Attou D; Benskhria S; Gratecos L
    Arch Pediatr; 2000 Apr; 7(4):429. PubMed ID: 10793937
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospects for a respiratory syncytial virus vaccine.
    Hall CB
    Science; 1994 Sep; 265(5177):1393-4. PubMed ID: 7915433
    [No Abstract]   [Full Text] [Related]  

  • 3. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus--is it preventable?
    Ruuskanen O
    J Hosp Infect; 1995 Jun; 30 Suppl():494-7. PubMed ID: 7560988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin.
    Meissner HC; Welliver RC; Chartrand SA; Fulton DR; Rodriguez WJ; Groothuis JR
    Pediatr Infect Dis J; 1996 Dec; 15(12):1059-68. PubMed ID: 8970212
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
    O'Shea TM; Sevick MA; Givner LB
    Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nosocomial infections due to syncytial respiratory virus: which hygienic measures].
    Sizun J; Baron R; Soupre D; Giroux JD; de Parscau L
    Arch Pediatr; 1996 Jul; 3(7):723-7. PubMed ID: 8881187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
    Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
    Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New vaccines against mucosal pathogens: rotavirus and respiratory syncytial virus.
    Coffin SE; Offit PA
    Adv Pediatr Infect Dis; 1997; 13():333-48. PubMed ID: 9544318
    [No Abstract]   [Full Text] [Related]  

  • 11. Respiratory syncytial virus seasonality and its implications on prevention strategies.
    Janet S; Broad J; Snape MD
    Hum Vaccin Immunother; 2018 Jan; 14(1):234-244. PubMed ID: 29194014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vaccines against respiratory syncytial virus].
    Freymuth F; Vabret A; Gouarin S; Gueudin M; Petitjean J
    Arch Pediatr; 1999; 6 Suppl 3():650s-654s. PubMed ID: 10429808
    [No Abstract]   [Full Text] [Related]  

  • 13. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
    Wright PF; Karron RA; Belshe RB; Shi JR; Randolph VB; Collins PL; O'Shea AF; Gruber WC; Murphy BR
    Vaccine; 2007 Oct; 25(42):7372-8. PubMed ID: 17868959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.
    Delgado MF; Polack FP
    Expert Rev Vaccines; 2004 Dec; 3(6):693-700. PubMed ID: 15606354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in and the potential of vaccines for respiratory syncytial virus.
    Jorquera PA; Oakley KE; Tripp RA
    Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal IgG Levels Correlate Better with Respiratory Syncytial Virus Load and Inflammation than Plasma IgG Levels.
    Vissers M; Ahout IM; de Jonge MI; Ferwerda G
    Clin Vaccine Immunol; 2015 Dec; 23(3):243-5. PubMed ID: 26656116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of respiratory syncytial virus infection in infants.
    Handforth J; Sharland M; Friedland JS
    BMJ; 2004 May; 328(7447):1026-7. PubMed ID: 15117767
    [No Abstract]   [Full Text] [Related]  

  • 18. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus: reverse genetics and vaccine strategies.
    Collins PL; Murphy BR
    Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
    [No Abstract]   [Full Text] [Related]  

  • 20. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
    Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.